Spruce Biosciences Common Net Asset
| SPRB Stock | USD 56.50 -0.07 -0.12% |
| = | 53.02 M |
Spruce Biosciences' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets are sold, the net asset will be the amount that the shareholders would demand back from the fund.
Net Asset | = | Current Market Value | - | Current Liabilities |
Current Spruce Biosciences Net Asset | 53.02 M |
Net Asset adds to the valuation picture for Spruce Biosciences Common by measuring one side of financial results. Checking Spruce Biosciences' market valuation against core benchmarks shows if the stock is priced for growth or value. The size of the gap between market price and core value can show the strength of a possible chance. These metrics give one lens through which to view Spruce Biosciences' investment potential. A price-to-book ratio of 3.59 helps frame the market's assessment of Spruce Biosciences' asset base.
Net Asset Driver Correlations
Mapping Net Asset against Spruce Biosciences' other financial drivers surfaces the strongest account-level relationships. Clusters of correlated accounts often correspond to distinct business segments or cost centers at Spruce Biosciences.
Click cells to compare fundamentals
| Competition |
Spruce Total Assets
Total Assets | $80.67 million |
Fundamental Drivers Relationships
Net Asset Peer Comparison
Stock peer comparison using Net Asset is a widely accepted framework for evaluating Spruce Biosciences within its group. Investors who find Spruce Biosciences' Net Asset more favorable than peers may view Spruce Biosciences as attractively valued. Peer dispersion in Net Asset across the group provides context for evaluating Spruce Biosciences' competitive positioning. This Net Asset peer data helps refine the view of Spruce Biosciences' relative attractiveness.Spruce Biosciences is currently under evaluation in net asset among leading competitors.
Institutional Holders
The institutional ownership of Spruce Biosciences reflects the concentration of Spruce Biosciences' shares among large entities. Because these investors hold large blocks of stock, they can meaningfully influence Spruce Biosciences' corporate direction. Rising institutional ownership in Spruce Biosciences may signal growing confidence among professional money managers. This data provides useful context for evaluating the stability of Spruce Biosciences's shareholder base.| Shares | Quinn Opportunity Partners Llc | 2025-12-31 | 22.8 K | Caligan Partners Lp | 2025-12-31 | 20.5 K | Stonepine Capital Management Llc | 2025-12-31 | 19.7 K | Vanguard Group Inc | 2025-12-31 | 17.9 K | Blackrock Inc | 2025-12-31 | 16.9 K | Geode Capital Management, Llc | 2025-12-31 | 12.7 K | Superstring Capital Management Lp | 2025-12-31 | 12.1 K | State Street Corp | 2025-12-31 | 6.4 K | Resolute Capital Asset Partners Llc | 2025-12-31 | 4 K | Ikarian Capital, Llc | 2025-12-31 | 121.4 K | Squadron Capital Management Llc | 2025-12-31 | 70 K |
Important Fundamentals
| Return On Equity TTM | -1.09 | |||
| Return On Asset TTM | -0.36 | |||
| Current Valuation | 104.51 M | |||
| Shares Outstanding | 2.7 M | |||
| Shares Owned By Insiders | 3.61 % | |||
| Shares Owned By Institutions | 34.20 % | |||
| Number Of Shares Shorted | 180.54 K | |||
| Price To Book TTM | 3.59 X | |||
| Price To Sales TTM | 49.19 X | |||
| Gross Profit TTM | -13.62 M | |||
| EBITDA TTM | -36.51 M | |||
| Net Income TTM | -38.97 M | |||
| Cash And Equivalents TTM | 93.3 M | |||
| Cash Per Share TTM | 3.96 X | |||
| Total Debt TTM | 736 K | |||
| Debt To Equity TTM | 0.07 % | |||
| Current Ratio TTM | 9.55 X | |||
| Book Value Per Share TTM | 30.99 X | |||
| Cash Flow From Operations TTM | -33.33 M | |||
| Short Ratio TTM | 3.41 X | |||
| Earnings Per Share | -50.83 X | |||
| Target Price | 186.6 | |||
| Trailing Beta | 3.31 | |||
| Market Capitalization TTM | 152.68 M | |||
| Total Asset TTM | 53.02 M | |||
| Retained Earnings TTM | -289.23 M | |||
| Working Capital TTM | 42.03 M | |||
| Net Asset | 53.02 M |
Financial Metrics, Fundamentals & Methodology
Spruce Biosciences's operating framework helps explain margin behavior, earnings persistence, and funding capacity. Operating leverage helps explain how sensitive earnings may be to slower demand or higher costs. For the latest reporting period, Spruce Biosciences reports EPS loss of 50.83, current ratio of 9.55, debt-to-equity of 0.07.
Reported values for Spruce Biosciences Common are derived from periodic company reporting and market reference feeds and standardized for analysis. Accounting-line values follow GAAP or IFRS structures as published in issuer filings.
Editorial review and methodology oversight provided by: Gabriel Shpitalnik, Member of Macroaxis Editorial Board